

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2002, 22:30:16 ; Search time 300 Seconds
(without alignments)
4278.797 Million cell updates/sec

Title: US-09-895-298A-32_COPY_63_632
Perfect score: 570
Sequence: 1 atgatgaatttcacgctcc.....aagaaggtatccaagggcc 570

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_101002:*

1:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24:	/SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	570	100.0	1461	21	AAA78402	Human secreted pro
2	568.4	99.7	1097	22	ABA08605	Human LAK-4p homol
3	568.4	99.7	1097	22	AAK53221	Human polynucleoti
4	568.4	99.7	1219	22	AAF82463	Human CASB6411-rel
5	568.4	99.7	1312	22	AAK52237	Human polynucleoti
6	568.4	99.7	1813	22	AAH18131	Human CDNA sequenc
7	568.4	99.7	1960	22	AAF82462	Human CASB6411-rel
8	568.4	99.7	2243	21	AAA64684	CDNA encoding a hu
9	568.4	99.7	2407	22	AAF82460	Human CASB6411 CDN

10	568.4	99.7	2521	22	AAF82461	Alternatively spli
11	548.4	96.2	1194	23	ABV22463	Human prostate exp
12	548.4	96.2	1194	23	ABV25683	Human prostate exp
13	548.4	96.2	1194	23	ABV28278	Human prostate exp
14	363	63.7	501	22	ABV09919	Human breast cancer
15	362.4	63.6	470	22	ABV18591	Human breast cancer
16	211.6	37.1	617	23	ABV12915	Human prostate exp
17	210.4	36.9	286	23	ABV08852	Human prostate exp
18	202	35.4	777	22	AAH08034	Human CDNA clone (
19	180.6	31.7	233	22	ABV10187	Human breast cancer
20	168.6	29.6	197	22	AAH1967	Human breast cancer
21	155.4	27.3	590	23	ABV34041	Human prostate exp
22	155.4	27.3	590	23	ABV42908	Human prostate exp
23	149.8	26.3	555	22	AAH20351	Human breast cancer
24	127.2	22.3	402	22	ABV58847	Novel human polynu
25	105.4	18.5	454	22	ABV58847	Human foetal liver
26	105.4	18.5	454	22	AAK07004	Human brain expres
27	105.4	18.5	454	22	AAK32745	Human bone marrow
28	105.4	18.5	454	22	AAI38558	Probe #7244 used t
29	105.4	18.5	454	24	ABV0543	Human genome-deriv
30	100.4	17.6	2902	24	ABV054905	Human ovarian anti
31	94.4	16.6	498	22	AAH11452	Human breast cancer
32	94	16.5	94	22	ABA71379	Human foetal liver
33	94	16.5	94	22	AAK19696	Human brain expres
34	94	16.5	94	22	AAK45716	Human bone marrow
35	94	16.5	94	22	AAI51641	Probe #20327 used
36	94	16.5	94	24	ABV19993	Human genome-deriv
37	87.4	15.3	523	23	ABV03746	Human prostate exp
38	51.8	9.1	545	20	AAK20418	Human secreted pro
39	46.4	8.1	617	22	AAH11030	Human breast cancer
40	46.4	8.1	618	22	AAH18794	Human breast cancer
41	41.6	7.3	775	22	AAH20104	Human breast cancer
42	36.4	6.4	7032	23	AAK42542	Genomic sequence #
43	36.4	6.4	8622	21	AAK59512	Human Kik-L3 gene.
44	35.8	6.3	297	23	AAK90725	DNA encoding novel
45	35.8	6.3	317	22	AAK39211	Novel human diagno

ALIGNMENTS

RESULT 1	AAA78402
ID	AAA78402 standard; CDNA; 1461 BP.
XX	AAA78402;
AC	20-NOV-2000 (first entry)
XX	
DT	Human secreted protein gene 22 SEQ ID NO:32.
XX	
DE	
XX	Human; secreted protein; cytosolic; antianaemic; antidiabetic;
KW	antiinflammatory; ophthalmological; antirheumatic; antithrilitic;
KW	antiporiatic; antiangiogenic; cardiant; anti-HIV; nootropic;
KW	neuroprotective; antimicrobial; antiparkinsonian; cancer;
KW	immune system disorder; angiogenesis; hyperproliferative disorder;
KW	cardiovascular disorder; apoptosis; neurological disease;
KW	infectious disease; wound healing; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200035937-A1.
XX	
PD	22-JUN-2000.
XX	
PF	16-DEC-1999; 99MO-US29950.
XX	
PR	17-DEC-1998; 98US-0112809.
PR	18-DEC-1998; 98US-0113006.
XX	
PA	(HUMA-) HUMAN GENOME SCI INC.
XX	
PI	Ruben SM, Ebner R, Rosen CA, Endress GA, Soppet DR, Ni J;

PI Duan DR, Moore PA, Shi Y, Lafleur DW, Oisen HS, Florence R;
XX
DR WPI; 2000-431566/37.
DR P-PSDB; AAB24458.
XX
PT Forty seven human nucleic acids encoding secreted proteins, useful in
PT the treatment, prevention and diagnosis of cancers, disorders of the
PT immune system, angiogenesis disorders, neurological diseases and
PT hyperproliferative disorders -
XX
PS Claim 1; Page 457-458; 562pp; English.
XX
CC The polynucleotide sequence given in AAA78381 to AAA78432 encode the
CC human secreted proteins given in AAB24437 to AAB24604. Human secreted
CC proteins have activities based on the tissues and cells the genes are
CC expressed in. Examples of activities include: cytostatic; antianaemic;
CC antidiabetic; antiinflammatory; ophthalmological; antirheumatic;
CC antiarthritic; antipsoriatic; antiangiogenic; cardiant; anti-HIV;
CC neurotropic; neuroprotective; antimicrobial and antiparkinsonian.
CC Human secreted protein polynucleotides, polypeptides, antagonists and/or
CC agonists may be useful in treating, preventing, and/or diagnosing other
CC diseases, disorders, and/or conditions such as: (a) cancers; (b)
CC disorders of the immune system; (c) angiogenesis disorders; (d)
CC hyperproliferative disorders; (e) cardiovascular disorders; (f) diseases
CC associated with increase apoptosis; (g) neurological diseases; and
CC (h) infectious diseases. They are also used to promote wound healing.
CC AAA78372 to AAA78380 and AAB24436 represent sequences used in the
CC exemplification of the present invention.
XX
XX

Sequence 1461 BP; 428 A; 312 C; 324 G; 397 T; 0 other;

Query Match 100.0%; Score 570; DB 21; Length 1461;
Best Local Similarity 100.0%; Pred. No. 1.9e-166;
Matches 570; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCCTCCAGCAAAAGCCTGGCGGCGCTCACAGATGATGACTTTCTTC 60
DB 63 ATGATGAATTTCCAGCCTCCAGCAAAAGCCTGGCGGCGCTCACAGATGATGACTTTCTTC 122
QY 61 ATCTCTGCTCTTTTCCATCTTTCACCGGGCTCTTGACACCCCTGGCCATCACCATC 120
DB 123 ATCTCTGCTCTTTTCCATCTTTCACCGGGCTCTTGACACCCCTGGCCATCACCATC 182
QY 121 TGGAGATTGAAGCCTTCAGCTGAGCTGCGCCCTTTTCGAGTCTGCTCTTCATTTCAC 180
DB 183 TGGAGATTGAAGCCTTCAGCTGAGCTGCGCCCTTTTCGAGTCTGCTCTTCATTTCAC 242
QY 181 TCCATCTACAGCTGGATGCAACCCCTAAGTACACGGCCCTGCTACTGTGGTGTGG 240
DB 243 TCCATCTACAGCTGGATGCAACCCCTAAGTACACGGCCCTGCTACTGTGGTGTGG 302
QY 241 ATCTATCGGAACCTTCATTTGAGAGTGTGCACTTTTTCATCTCTCACCCCTCATTTGCTA 300
DB 303 ATCTATCGGAACCTTCATTTGAGAGTGTGCACTTTTTCATCTCTCACCCCTCATTTGCTA 362
QY 301 ATCATCACCCTATCTTACTGCGAGATCACAGAGGGAAGATTAATGATAAGGCTGCTC 360
DB 363 ATCATCACCCTATCTTACTGCGAGATCACAGAGGGAAGATTAATGATAAGGCTGCTC 422
QY 361 CATGAGCAGATCATTAATGAGGGCAAAAGATAAATGTCTCGATAGAAAATTTGATCAAG 420
DB 423 CATGAGCAGATCATTAATGAGGGCAAAAGATAAATGTCTCGATAGAAAATTTGATCAAG 482
QY 421 CTGCAGATATGAGAGAAAAGCAAAACCCAGCTCCTGTTCTGTGAAAAGAGAGAGGTG 480
DB 483 CTGCAGATATGAGAGAAAAGCAAAACCCAGCTCCTGTTCTGTGAAAAGAGAGAGGTG 542
QY 481 GAGCAACAAGGCTTTTGCATTTGGGGGAACATGATGGCAGTCTTACTTGGCATCTAGA 540
DB 543 GAGCAACAAGGCTTTTGCATTTGGGGGAACATGATGGCAGTCTTACTTGGCATCTAGA 602
QY 541 AGATCAGTTCAAGAGGTAAATCCAAGGGCC 570
|||||

DB 603 AGATCAGTTCAAGAGGTAAATCCAAGGGCC 632
RESULT 2
ID ABA08605 standard; cDNA; 1097 BP.
AC ABA08605;
XX 11-JAN-2002 (first entry)
DT Human LAK-4p homologue-encoding cDNA, SEQ ID NO:381.
XX
DE Human; cytokine; cell proliferation; cell differentiation; growth factor;
KW haematopoiesis regulation; tissue growth; immunomodulator; activin;
KW inhibin; chemotaxis; chemokinesis; thrombolytic; oncogenesis;
KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;
KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
KW chronic inflammatory condition; proliferative retinopathy;
KW atherosclerosis; coronary heart disease; arterial ischaemia;
KW bone disorder; osteoporosis; vascular growth disorder;
KW tissue regeneration; wound healing; infection; immune disorder;
KW cell culture; drug screening; gene therapy; antiinflammatory;
KW antiasthmatic; antiarthritic; haemostatic; antiarteriosclerotic;
KW cytostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;
KW antifungal; vulnery; antilucer; ss.
OS Homo sapiens.
XX
PN WO200157188-A2.
XX
XX 09-AUG-2001.
XX
XX 05-FEB-2001; 2001WO-US03800.
XX
XX 03-FEB-2000; 2000US-0496914.
PR 27-APR-2000; 2000US-0560875.
XX
XX (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
PI
XX WPI; 2001-457740/49.
DR P-PSDB; ABB11361.
XX
PT Human proteins and DNA encoding sequences useful for preventing,
PT treating or ameliorating a medical condition in a mammalian subject
PT e.g. arthritis and cancer -
PS
PS Claim 1; Page 473; 1963pp; English.
XX
CC Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and
CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The
CC invention also relates to vectors and recombinant host cells comprising a
CC nucleotide of the invention, methods of producing the novel polypeptides,
CC antibodies against the polypeptides, methods of detecting the nucleotides
CC or polypeptides in a sample, and methods of identifying compounds which
CC bind to polypeptides of the invention. Although novel, many of the
CC polypeptides of the invention have homology to known proteins, thereby
CC giving an insight into their probable biological activities, and hence
CC potential therapeutic applications. The polypeptides of the invention may
CC have various activities, including cytokine, cell proliferation or cell
CC differentiation activities; stem cell growth factor activity;
CC haematopoiesis regulatory activity; tissue growth activity;
CC immunomodulatory activity; activin- or inhibin-related activities;
CC chemotactic or chemokinetic activities; haemostatic, thrombotic or
CC thrombolytic activities; receptor or ligand activities; or may be
CC involved in oncogenesis, cancer cell proliferation or metastasis.
CC Depending on their biological activities, polypeptides and nucleotides of
CC the invention are useful for preventing, treating or ameliorating medical
CC conditions, e.g., by protein or gene therapy. Such conditions include
CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell
CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),

CC proliferative retinopathy, atherosclerosis, coronary heart disease,
CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
CC vascular growth. Polypeptides involved with tissue regeneration and
CC repair (or nucleic acids encoding them) may be used to promote wound
CC healing (e.g., of burns, incisions and ulcers), while those with
CC immunomodulatory activities may be used in the treatment of viral,
CC bacterial and fungal infections in addition to immune disorders.
CC Polypeptides with growth factor activity may be used in cell cultures to
CC promote cell growth. For example, such polypeptides may be used to
CC manipulate stem cells in culture to give rise to neuroepithelial cells
CC that can be used to augment or replace cells damaged by illness,
CC autoimmune disease or accidental damage. The polypeptides and nucleotides
CC may also be used in the diagnosis of the above conditions, and in drug
CC screening techniques. The present sequence represents a cDNA encoding a
CC novel human polypeptide of the invention.

XX Sequence 1097 BP; 288 A; 246 C; 247 G; 316 T; 0 other;

Query Match 99.7%; Score 568.4; DB 22; Length 1097;
Best Local Similarity 99.8%; Pred. No. 5.2e-166;
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCCTCCGAGCAAAAGCCTGGCGGCTCACAGATGACTTCTTC 60
DB 269 ATGATGAATTTCCAGCCTCCGAGCAAAAGCCTGGCGGCTCACAGATGACTTCTTC 328
QY 61 ATCTTCTTGCTCTTTTCCCATCTTTCACCGGGGCTTGTGACACCTGGCCATCACCATC 120
DB 329 ATCTTCTTGCTCTTTTCCCATCTTTCACCGGGGCTTGTGACACCTGGCCATCACCATC 388
QY 121 TGGAGATTGAAGCCTTCAGCTGACTGTGCGCCTTTTCGAGGTCTGCTCTTCATTAC 180
DB 389 TGGAGATTGAAGCCTTCAGCTGACTGTGCGCCTTTTCGAGGTCTGCTCTTCATTAC 448
QY 181 TCCATCTACAGCTGGATGCACACCTTAAGTACACGCGCTGCTACCTGTGGGTTGTTGG 240
DB 449 TCCATCTACAGCTGGATGCACACCTTAAGTACACGCGCTGCTACCTGTGGGTTGTTGG 508
QY 241 ATCTATCGGAACCTCATTTGGAAGTGTGCATCTTTCATCCCTCACCCCATTTGCTA 300
DB 509 ATCTATCGGAACCTCATTTGGAAGTGTGCATCTTTCATCCCTCACCCCATTTGCTA 568
QY 301 ATCATCACTATCTTACTGTCAGATCACAGAGGGAAGAAATATGATTAAGGCTGCTC 360
DB 569 ATCATCACTATCTTACTGTCAGATCACAGAGGGAAGAAATATGATTAAGGCTGCTC 628
QY 361 CATGACGACATCATTAATAGGGGCAAAAGATATAATGTTCTGTATAGAAAATTTGATCAAG 420
DB 629 CATGACGACATCATTAATAGGGGCAAAAGATATAATGTTCTGTATAGAAAATTTGATCAAG 688
QY 421 CTGACGATATGAGAGAAGCAAAAGCCAGCTCATTGTCTGGAAGAGAGAGGTG 480
DB 689 CTGACGATATGAGAGAAGCAAAAGCCAGCTCATTGTCTGGAAGAGAGAGGTG 748
QY 481 GAGCAACAAGGCTTTTTCATTTGGGGGAACATGATGCGAGTCTTGACTTGCATCTAGA 540
DB 749 GAGCAACAAGGCTTTTTCATTTGGGGGAACATGATGCGAGTCTTGACTTGCATCTAGA 808
QY 541 AGATCAGTTCAGAAGGTAATCCAGGGCC 570
DB 809 AGATCAGTTCAGAAGGTAATCCAGGGCC 838

RESULT 3
AAK53221
ID AAK53221 standard; cDNA; 1097 BP.

XX AAK53221;

DT 06-NOV-2001 (first entry)

DE Human polynucleotide SEQ ID NO 2750.

XX

KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorder; arthritis; inflammation; ss.

OS Homo sapiens.

PN WO200157190-A2.

PD 09-AUG-2001.

PF 05-FEB-2001; 2001WO-US04098.

PR 03-FEB-2000; 2000US-0496914.

PR 27-APR-2000; 2000US-0560875.

PR 20-JUN-2000; 2000US-0598075.

PR 19-JUL-2000; 2000US-0620325.

PR 01-SEP-2000; 2000US-0654936.

PR 15-SEP-2000; 2000US-0663561.

PR 20-OCT-2000; 2000US-0693325.

PR 30-NOV-2000; 2000US-0728422.

XX (HYSE-) HYSEQ INC.

XX Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;
PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;
XX WPI; 2001-476283/51.
DR P-PSDB; AAM80088.

PT Nucleic acids encoding polypeptides with cytokine-like activities,
PT useful in diagnosis and gene therapy -
XX Claim 1; Page 4962; 6221pp; English.

XX The invention relates to polynucleotides (AAK51456-AAK53435) and the
CC encoded polypeptides (AAM78323-AAM80302) that exhibit activity relating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666
CC (AAM80020) are omitted as the relevant pages from the sequence listing
CC were missing at the time of publication.

XX Sequence 1097 BP; 288 A; 246 C; 247 G; 316 T; 0 other;

Query Match 99.7%; Score 568.4; DB 22; Length 1097;
Best Local Similarity 99.8%; Pred. No. 5.2e-166;
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCCTCCGAGCAAAAGCCTGGCGGCTCACAGATGACTTCTTC 60
DB 269 ATGATGAATTTCCAGCCTCCGAGCAAAAGCCTGGCGGCTCACAGATGACTTCTTC 328
QY 61 ATCTTCTTGCTCTTTTCCCATCTTTCACCGGGGCTTGTGACACCTGGCCATCACCATC 120
DB 329 ATCTTCTTGCTCTTTTCCCATCTTTCACCGGGGCTTGTGACACCTGGCCATCACCATC 388
QY 121 TGGAGATTGAAGCCTTCAGCTGACTGTGCGCCTTTTCGAGGTCTGCTCTTCATTAC 180
DB 389 TGGAGATTGAAGCCTTCAGCTGACTGTGCGCCTTTTCGAGGTCTGCTCTTCATTAC 448
QY 181 TCCATCTACAGCTGGATGCACACCTTAAGTACACGCGCTGCTACCTGTGGGTTGTTGG 240
DB 449 TCCATCTACAGCTGGATGCACACCTTAAGTACACGCGCTGCTACCTGTGGGTTGTTGG 508

QY 241 ATCTATCGAACCTCATTTGAGAGTGTGCACTTTTTCATCCCTCACTTGTGCTA 300
|||||
Db 509 ATCTATCGGAACCTCATTTGAGAGTGTGCACTTTTTCATCCCTCACTTGTGCTA 568
QY 301 ATCATCACCCTATCTTTACTGCGACATACAGAGGGAAGATTATGATAAGGCTGCTC 360
|||||
Db 569 ATCATCACCCTATCTTTACTGCGACATACAGAGGGAAGATTATGATAAGGCTGCTC 628
QY 361 CATGAGCAGATCATTAATGAGGGCAAGATTAATGTTCTGATAGAAAAATGATCAAG 420
|||||
Db 629 CATGAGCAGATCATTAATGAGGGCAAGATTAATGTTCTGATAGAAAAATGATCAAG 688
QY 421 CTGCAAGATATGAGAAAGCAAAACCCAGCTCAGTTGTTCTGAGAAAGAGAGAGGTG 480
|||||
Db 689 CTGCAAGATATGAGAAAGCAAAACCCAGCTCAGTTGTTCTGAGAAAGAGAGAGGTG 748
QY 481 GAGCAACAAGGCTTTTTCATTTGGGGACATGATGCACTTGTGACTTGGCATCTAGA 540
|||||
Db 749 GAGCAACAAGGCTTTTTCATTTGGGGACATGATGCACTTGTGACTTGGCATCTAGA 808
QY 541 AGATCAGTTCAAGAAGTAAATCCAAAGGCC 570
|||||
Db 809 AGATCAGTTCAAGAAGTAAATCCAAAGGCC 838

RESULT 4
AAF82463
ID AAF82463 standard; cDNA; 1219 BP.
XX
AC AAF82463;
XX
DT 29-JUN-2001 (first entry)
XX
DE Human CASB6411-related cDNA #2.
XX
KW Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;
KW ovarian cancer; colon cancer; autoimmune disease; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..576
FT /*tag= a
FT /partial
FT /note= "this sequence does not contain a start codon"
XX
PN WO200123417-A2.
XX
PD 05-APR-2001.
XX
PF 27-SEP-2000; 2000WO-EP09500.
XX
PR 30-SEP-1999; 99GB-0023154.
PR 07-JUL-2000; 2000GB-0016839.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Vinals De Bassols YC;
XX
DR WPI; 2001-316133/33.
DR P-PSDB; AAB83082.
XX
PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for
PT prophylactic and therapeutic treatment of cancers, particularly ovarian
PT and colon cancers, autoimmune diseases and related conditions -
XX
PS Claim 32; Page 66-67; 95pp; English.
XX
CC The present sequence is provided in a specification relating
CC to CASB6411 polypeptides comprising a sequence having at least 70%
CC identity to a sequence of 460 or 154 amino acids fully defined in
CC the specification. CASB6411 polypeptides and polynucleotides are
CC useful for treating a subject by immunoprophylaxis or therapy.

CC The CASB6411 polypeptides are useful in diagnostics, and as
CC vaccines for prophylactic and therapeutic treatment of cancers, related
CC particularly ovarian and colon cancers, autoimmune diseases and related
CC conditions. CASB6411 polypeptides are also useful for the
CC structure-based design of agonists, antagonists or inhibitors of the
CC polypeptide.
XX

SO Sequence 1219 BP; 346 A; 260 C; 275 G; 338 T; 0 other;

Query Match

99.7%; Score 568.4; DB 22; Length 1219;

Best Local Similarity 99.8%; Pred. No. 5.5e-166;

0;

Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCACCTCCGAGCAAGCCTGGGGGCTCAGATGATGACTTTCTTC 60
|||||
Db 4 ATGATGAATTTCCACCTCCGAGCAAGCCTGGGGGCTCAGATGATGACTTTCTTC 63
QY 61 ATCTTCTGCTCTTTTCCCACTTTTCAACCGGGGCTTGTGACCCCTGGCCATCACCATC 120
|||||
Db 64 ATCTTCTGCTCTTTTCCCACTTTTCAACCGGGGCTTGTGACCCCTGGCCATCACCATC 123
QY 121 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTTCGAGGCTGCTCTTCATTCAC 180
|||||
Db 124 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTTCGAGGCTGCTCTTCATTCAC 183
QY 181 TCCATCTACAGCTGATGACACCCCTAAGTACACGGCCCTGCTACCTGCTGTTGG 240
|||||
Db 184 TCCATCTACAGCTGATGACACCCCTAAGTACACGGCCCTGCTACCTGCTGTTGG 243
QY 241 ATCTATCGGAACCTCATTTGAGAGTGTGCACTTTTTCATCCCTCACTTGTGCTA 300
|||||
Db 244 ATCTATCGGAACCTCATTTGAGAGTGTGCACTTTTTCATCCCTCACTTGTGCTG 303
QY 301 ATCATCACTATCTTTACTGCGACATCACAGAGGGAAGATTATGATAAGGCTGCTC 360
|||||
Db 304 ATCATCACTATCTTTACTGCGACATCACAGAGGGAAGATTATGATAAGGCTGCTC 363
QY 361 CATGAGCAGATCATTAATGAGGGCAAGATTAATGTTCTGATAGAAAAATGATCAAG 420
|||||
Db 364 CATGAGCAGATCATTAATGAGGGCAAGATTAATGTTCTGATAGAAAAATGATCAAG 423
QY 421 CTGCAAGATATGAGAAAGCAAAACCCAGCTCAGTTGTTCTGAGAAAGAGAGGTG 480
|||||
Db 424 CTGCAAGATATGAGAAAGCAAAACCCAGCTCAGTTGTTCTGAGAAAGAGAGGTG 483
QY 481 GAGCAACAAGGCTTTTTCATTTGGGGACATGATGCGCTTGTGACTTGGCATCTAGA 540
|||||
Db 484 GAGCAACAAGGCTTTTTCATTTGGGGACATGATGCGCTTGTGACTTGGCATCTAGA 543
QY 541 AGATCAGTTCAAGAAGTAAATCCAAAGGCC 570
|||||
Db 544 AGATCAGTTCAAGAAGTAAATCCAAAGGCC 573

RESULT 5
AAK52237

ID AAK52237 standard; cDNA; 1312 BP.

XX AAK52237;

XX 06-NOV-2001 (first entry)

XX Human polynucleotide SEQ ID NO 782.

XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;

XX vaccine; peptide therapy; stem cell growth factor; haematopoiesis;

XX tissue growth factor; immunomodulatory; cancer; leukaemia;

XX nervous system disorder; arthritis; inflammation; ss.

XX Homo sapiens.
OS
XX
PN WO200157190-A2.
XX

PD 09-AUG-2001.
XX
PF 05-FEB-2001; 2001WO-US04098.
XX
XX 03-FEB-2000; 2000US-0496914.
PR 27-APR-2000; 2000US-0560875.
PR 20-JUN-2000; 2000US-0598075.
PR 19-JUL-2000; 2000US-0620325.
PR 01-SEP-2000; 2000US-0654936.
PR 15-SEP-2000; 2000US-0663561.
PR 20-OCT-2000; 2000US-0693325.
PR 30-NOV-2000; 2000US-0728422.
XX
PA (HYSE-) HYSEQ INC.
PI Tang YF, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;
PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;
XX
XX WPI; 2001-476283/51.
DR P-PSDB; AAM79104.
XX
XX Nucleic acids encoding polypeptides with cytokine-like activities,
PT useful in diagnosis and gene therapy -
PS Claim 1; Page 2615-2616; 6221pp; English.
XX
XX The invention relates to polynucleotides (AAK51456-AAK53435) and the
CC encoded polypeptides (AAM78323-AAK80302) that exhibit activity elating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666
CC (AAM80020) are omitted as the relevant pages from the sequence listing
CC were missing at the time of publication.
XX
SQ Sequence 1312 BP; 370 A; 286 C; 287 G; 369 T; 0 other;
Query Match 99.7%; Score 568.4; DB 22; Length 1312;
Best Local Similarity 99.8%; Pred. No. 5.8e-166;
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 ATGATGATTTTCAGCCTCCGAGCAAGCCCTGGCGGCTCAGATGATGACTTCTTC 60
DB 294 ATGATGATTTTCAGCCTCCGAGCAAGCCCTGGCGGCTCAGATGATGACTTCTTC 353
QY 61 ATCTTCTGCTTTTCCCATCTTTCACCGGGGCTGTGACACCTGGCCATCACCATC 120
DB 354 ATCTTCTGCTTTTCCCATCTTTCACCGGGGCTGTGACACCTGGCCATCACCATC 413
QY 121 TGGAGATGAAGCCTTCAGCTGCTGCGCCCTTTTCGAGGTGCTGCTCTTCATTAC 180
DB 414 TGGAGATGAAGCCTTCAGCTGCTGCGCCCTTTTCGAGGTGCTGCTCTTCATTAC 473
QY 181 TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGGCTGCTACTGTGGGTGTTGG 240
DB 474 TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGGCTGCTACTGTGGGTGTTGG 533
QY 241 ATCTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTCATCCTCACCCTCATTTGCTA 300
DB 534 ATCTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTCATCCTCACCCTCATTTGCTA 593
QY 301 ATCATCACTATCTTACATGCGAGATCAGAGGGAAGAGATTAATGATAAGGCTGTC 360
DB 594 ATCATCACTATCTTACATGCGAGATCAGAGGGAAGAGATTAATGATAAGGCTGTC 653
QY 361 CATGAGCAGATCATTAATGAGGGCAAGATAAATGTTCTGATGAAAAAATTGATCAAG 420

DB 654 CATGAGCAGATCATTAATGAGGGCAAGATAAATGTTCTGATGAAAAAATTGATCAAG 713
QY 421 CTGACAGATATGAGAGAGAAAGCAAAACCCGACTGCTGTTGTTGGAAGAGAGAGGTG 480
DB 714 CTGACAGATATGAGAGAGAAAGCAAAACCCGACTGCTGTTGTTGGAAGAGAGAGGTG 773
QY 481 GAGCAACAAGGCTTTTTCGATTTGGGGGAACATGATGCGAGTCTTGACTTGCATCTAGA 540
DB 774 GAGCAACAAGGCTTTTTCGATTTGGGGGAACATGATGCGAGTCTTGACTTGCATCTAGA 833
QY 541 AGATCAGTTCAAGAAGGTAAATCCAAAGGCC 570
DB 834 AGATCAGTTCAAGAAGGTAAATCCAAAGGCC 863
RESULT 6
AAH18131
ID AAH18131 standard; cDNA; 1813 BP.
XX
XX AAH18131;
XX
XX 26-JUN-2001 (first entry)
DE Human cDNA sequence SEQ ID NO:18001.
XX
XX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
OS Homo sapiens.
XX
XX EP1074617-A2.
XX
XX 07-FEB-2001.
XX
XX 28-JUL-2000; 2000EP-0116126.
PF 29-JUL-1999; 99JP-0248036.
PR 27-AUG-1999; 99JP-0300253.
PR 11-JAN-2000; 2000JP-0118776.
PR 02-MAY-2000; 2000JP-0183767.
PR 09-JUN-2000; 2000JP-0241899.
XX
XX (HELI-) HELIX RES INST.
XX
XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
XX WPI; 2001-318749/34.
DR
XX
XX Primer sets for synthesising polynucleotides, particularly the 5602
PT full-length cDNAs defined in the specification, and for the detection
PT and/or diagnosis of the abnormality of the proteins encoded by the
PT full-length cDNAs -
XX
XX Claim 8; SEQ ID 18001; 2537bp + CD ROM; English.
PS
XX
XX The present invention describes primer sets for synthesising 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesising polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length

CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.

XX
SQ Sequence 1813 BP; 489 A; 400 C; 405 G; 519 T; 0 other;

Query Match 99.7%; Score 568.4; DB 22; Length 1813;
Best Local Similarity 99.8%; Pred. No. 6.9e-166;
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCAGCCTCCGAGCAAAAGCCTGGCGGCTCAGAGATGATGACTTCTTC 60
DB 451 ATGATGAATTTCAGCCTCCGAGCAAAAGCCTGGCGGCTCAGAGATGATGACTTCTTC 510
QY 61 ATCTTCTGCTCTTTTCCATCTTTACCCGGGCTCTTGACACCCCTGGCCATCACCATC 120
DB 511 ATCTTCTGCTCTTTTCCATCTTTACCCGGGCTCTTGACACCCCTGGCCATCACCATC 570
QY 121 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCTGCTCTTCATTCAC 180
DB 571 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCTGCTCTTCATTCAC 630
QY 181 TCCATCTACAGCTGATGACACCCCTAAGTACACGGCCCTGCTACCTGTGGTGTGG 240
DB 631 TCCATCTACAGCTGATGACACCCCTAAGTACACGGCCCTGCTACCTGTGGTGTGG 690
QY 241 ATCTATCGGAACCTTCATTTGAAGTGTGACCTTTTTCATCTCCACCCCTCATTTGCTA 300
DB 691 ATCTATCGGAACCTTCATTTGAAGTGTGACCTTTTTCATCTCCACCCCTCATTTGCTA 750
QY 301 ATCATCACCCTATCTTTACTGCGAGATACAGAGGGAAGATTATGATTAAGGCTGCTC 360
DB 751 ATCATCACCCTATCTTTACTGCGAGATACAGAGGGAAGATTATGATTAAGGCTGCTC 810
QY 361 CATGAGCAGATCATTAATGAGGGCAAAAGATTAATGTCTGATAGAAAAATGATCAAG 420
DB 811 CATGAGCAGATCATTAATGAGGGCAAAAGATTAATGTCTGATAGAAAAATGATCAAG 870
QY 421 CTGCAGATATGAGAGAAAGCAAAACCCAGCTCAGTGTCTTGGAAGAGAGAGAGGTG 480
DB 871 CTGCAGATATGAGAGAAAGCAAAACCCAGCTCAGTGTCTTGGAAGAGAGAGAGGTG 930
QY 481 GAGCAACAAGGCTTTTGCATTTGGGGGAACATGATGGAGTCTTGACTTGGCATCTAGA 540
DB 931 GAGCAACAAGGCTTTTGCATTTGGGGGAACATGATGGAGTCTTGACTTGGCATCTAGA 990
QY 541 AGATCAGTTCAAGAAGTAAATCCAAAGGCC 570
DB 991 AGATCAGTTCAAGAAGTAAATCCAAAGGCC 1020

RESULT 7
AAF82462
ID AAF82462 standard; cDNA; 1960 BP.
XX

AC AAF82462;
XX
DT 29-JUN-2001 (first entry)
XX
DE Human CASB6411-related cDNA #1.
XX
KW Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;
KM ovarian cancer; colon cancer; autoimmune disease; ss.
XX
OS Homo sapiens.

XX
FH Key Location/Qualifiers
FT CDS 1..1317
FT /*tag= a
FT /partial
FT /note="this sequence does not contain a start codon"

XX
PN WO200123417-A2.
XX
PD 05-APR-2001.
XX
PF 27-SEP-2000; 2000WO-EP09500.
XX
PR 30-SEP-1999; 99GB-0023154.
XX
PR 07-JUL-2000; 2000GB-0016839.
XX
PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

XX
PI Vinals De Bassols YC;
XX
DR WPI; 2001-316133/33.
XX
DR P-PSDB; AAB83081.

XX
PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for
XX prophylactic and therapeutic treatment of cancers, particularly ovarian
XX and colon cancers, autoimmune diseases and related conditions
XX
PS Claim 32; Page 65-66; 95pp; English.

XX
CC The present sequence is provided in a specification relating
CC to CASB6411 polypeptides comprising a sequence having at least 70%
CC identity to a sequence of 460 or 154 amino acids fully defined in
CC the specification. CASB6411 polypeptides and polynucleotides are
CC useful for treating a subject by immunoprophylaxis or therapy.
CC The CASB6411 polypeptides are useful in diagnostics, and as
CC vaccines for prophylactic and therapeutic treatment of cancers,
CC particularly ovarian and colon cancers, autoimmune diseases and related
CC conditions. CASB6411 polypeptides are also useful for the
CC structure-based design of agonists, antagonists or inhibitors of the
XX polypeptide.

SQ Sequence 1960 BP; 515 A; 439 C; 447 G; 559 T; 0 other;

Query Match 99.7%; Score 568.4; DB 22; Length 1960;
Best Local Similarity 99.8%; Pred. No. 7.2e-166;
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCAGCCTCCGAGCAAAAGCCTGGCGGCTCAGAGATGATGACTTCTTC 60
DB 745 ATGATGAATTTCAGCCTCCGAGCAAAAGCCTGGCGGCTCAGAGATGATGACTTCTTC 804
QY 61 ATCTTCTGCTCTTTTCCATCTTTCAACCGGGGCTTGTCACCCCTGGCCATCACCATC 120
DB 805 ATCTTCTGCTCTTTTCCATCTTTCAACCGGGGCTTGTCACCCCTGGCCATCACCATC 864
QY 121 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCTGCTCTTCATTCAC 180
DB 865 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCTGCTCTTCATTCAC 924
QY 181 TCCATCTACAGCTGATGACACCCCTAAGTACACGGCCCTGCTACCTGTGGGTGTTGG 240
DB 925 TCCATCTACAGCTGATGACACCCCTAAGTACACGGCCCTGCTACCTGTGGGTGTTGG 984
QY 241 ATCTATCGGAACCTATTTGAAGTGTGCACTTTTTCATCTCCTACCCCTCATTTGCTA 300
DB 985 ATCTATCGGAACCTATTTGAAGTGTGCACTTTTTCATCTCCTACCCCTCATTTGCTG 1044
QY 301 ATCATCACCCTATCTTTACTGCGAGATCACAGAGGGAAGATTATGATTAAGGCTGCTC 360
DB 1045 ATCATCACCCTATCTTTACTGCGAGATCACAGAGGGAAGATTATGATTAAGGCTGCTC 1104
QY 361 CATGAGCAGATCATTAATGAGGGCAAAAGATAAATGTTCTGTATGAAAAATTGATCAAG 420
DB 1105 CATGAGCAGATCATTAATGAGGGCAAAAGATAAATGTTCTGTATGAAAAATTGATCAAG 1164
QY 421 CTGCAGATATGAGAGAAAGCAAAACCCAGCTCAGTGTCTTGGAAGAGAGAGAGGTG 480
DB 1165 CTGCAGATATGAGAGAAAGCAAAACCCAGCTCAGTGTCTTGGAAGAGAGAGAGGTG 1224

PN WO200123417-A2.
XX
XX 05-APR-2001.
PD
XX
XX 27-SEP-2000; 2000WO-EP09500.
PF
XX 30-SEP-1999; 99GB-0023154.
PR 07-JUL-2000; 2000GB-0016839.
PR
XX
XX PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Vlnals De Bassols YC;
PI
XX
XX WPT; 2001-316133/33.
DR P-PSDB; AAB83079.
DR
XX
XX Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for
PT prophylactic and therapeutic treatment of cancers, particularly ovarian
PT and colon cancers, autoimmune diseases and related conditions -
XX
PS Claim 11; Page 63-64; 95pp; English.

CC The present sequence encodes human CASB6411 polypeptide. The
CC invention relates to CASB6411 polypeptides comprising a sequence
CC having at least 70% identity to a sequence of 460 or 154 amino acids
CC fully defined in the specification. CASB6411 polypeptides and
CC polynucleotides are useful for treating a subject by immunoprophylaxis
CC or therapy. The CASB6411 polypeptides are useful in diagnostics, and
CC as vaccines for prophylactic and therapeutic treatment of cancers,
CC particularly ovarian and colon cancers, autoimmune diseases and related
CC conditions. CASB6411 polypeptides are also useful for the
CC structure-based design of agonists, antagonists or inhibitors of the
CC polypeptide. The present sequence may be alternatively spliced to
CC generate a sequence encoding a truncated CASB6411 protein.
xx
SQ Sequence 2407 BP; 635 A; 557 C; 546 G; 669 T; 0 other;

Query Match	99.7%;	Score 568.4;	DB 22;	Length 2407;
Best Local Similarity	99.8%;	Pred. No. 8e-166;		
Matches 569;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;

QY	1	ATGATGAATTTTCCAGCCTCCGAGCAAAGCCTGCGGGCCTCAGAGATGATGACTTTCTTC	60
Db	1192	ATGATGAATTTCCAGCCTCCGAGCAAAGCCTGCGGGCCTCAGAGATGATGACTTTCTTC	1251
QY	61	ATCTCTTGCTCTTTTCCCATCTTTTCACCGGGGTCTGTGCACCCCTGGCCATCACCATC	120
Db	1252	ATCTCTTGCTCTTTTCCCATCTTTTCACCGGGGTCTGTGCACCCCTGGCCATCACCATC	1311
QY	121	TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTGGAGGTCTGCCCTCTTCATTCAC	180
Db	1312	TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTGGAGGTCTGCCCTCTTCATTCAC	1371
QY	181	TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGCCTGGCTACCTGTGGCTTGTGG	240
Db	1372	TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGCCTGGCTACCTGTGGCTTGTGG	1431
QY	241	ATCTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTCATCCACCCCTATTGTGCTA	300
Db	1432	ATCTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTCATCCACCCCTATTGTGCTA	1491
QY	301	ATCATCACCTATCTTTACTGCGCAGATCACAGAGGGAAGAGATTATGATTAAGGCTGCTC	360
Db	1492	ATCATCACCTATCTTTACTGCGCAGATCACAGAGGGAAGAGATTATGATTAAGGCTGCTC	1551
QY	361	CATGACGAGATCATTAATGAGGGCAAAAGATAAATGTTCCTGATAGAAAATTTGATCAAG	420
Db	1552	CATGACGAGATCATTAATGAGGGCAAAAGATAAATGTTCCTGATAGAAAATTTGATCAAG	1611
QY	421	CTGACGATATGAGAGAAAGCAAACCCGAGCTCATTGTTCTGGAAGGAGAGAGAGGTG	480
Db	1612	CTGACGATATGAGAGAAAGCAAACCCGAGCTCATTGTTCTGGAAGGAGAGAGAGGTG	1671

[illegible]

RESULT 10	
AAF82461	
ID	AAF82461 standard; cDNA; 2521 BP.

AC AAF82461;

DT 29-JUN-2001 (first entry)

DE Alternatively spliced human CASB6411 cDNA encoding truncated protein.

KW Human; CASB6411; vaccine; gene therapy; immunophylaxis;
KW ovarian cancer; colon cancer; autoimmune disease; isoform;
KW alternative splicing; ss.

OS Homo sapiens.

FH	Key	Location/Qualifiers
----	-----	---------------------

FT / *tag= a

XX

XX

XX

XX

PR 07-JUL-2000; 2000GB-0016839.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Vinals De Bassols YC;

DR WPI; 2001-316133/33.

XX

PT prophylactic and therapeutic treatment of cancers, particularly ovarian

XX

XX

CC is generated by alternative splicing of the full length human cDNA

CC comprising a sequence having at least 70% identity to a sequence of

CC polypeptides and polynucleotides are useful for treating a subject by

CC diagnostics, and as vaccines for prophylactic and therapeutic treatment

CC and related conditions. CASB6411 polypeptides are also useful for the

cc polypeptide.

SQ Sequence 2521 BP; 662 A; 583 C; 583 G; 693 T; 0 other;

Query Match 99.7%; Score 568.4; DB 22; Length 2521;

```
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

29 1 ATGATGATTTCCAGCCTCCGAGCAAGCCTGGCGGCTCACAGATGATGACTTCTTC 60

```
Db 1306 ATGATGAATTTCCAGCCCTCCGAGCAAGCCCTGGCGGCTCAGAGATGACTTCTTC 1365
QY 61 ATCTTGTGCTCTTTTCCATCTTTTCACCGGGGTCTTGTCACCCCTGGCCATCACATC 120
Db 1366 ATCTTGTGCTCTTTTCCATCTTTTCACCGGGGTCTTGTCACCCCTGGCCATCACATC 1425
QY 121 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCCTCTCTTCATTTCAC 180
Db 1426 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCCTCTCTTCATTTCAC 1485
QY 181 TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGCCTGGCTACCTGTGGTGTGG 240
Db 1486 TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGCCTGGCTACCTGTGGTGTGG 1545
QY 241 ATCTATCGAACCCTCATTTGGAAGTGTGCACCTTTTCATCTCTCACCCCTCATTTGTCTA 300
Db 1546 ATCTATCGAACCCTCATTTGGAAGTGTGCACCTTTTCATCTCTCACCCCTCATTTGTCTA 1605
QY 301 ATCATCACTATCTTTACTGCGACATCACAAGGGAAGGAAAGATTATGATTAAGGCTGCTC 360
Db 1606 ATCATCACTATCTTTACTGCGACATCACAAGGGAAGGAAAGATTATGATTAAGGCTGCTC 1665
QY 361 CATGACGAGATCATTTAATGAGGGCAAAAGATAAATGTTCTGTATGAAAAATTGATCAAG 420
Db 1666 CATGACGAGATCATTTAATGAGGGCAAAAGATAAATGTTCTGTATGAAAAATTGATCAAG 1725
QY 421 CTGACGATATGAGAAAGCAAAACCCCACTCATTGTTCTGAAAGAGAGAGAGTG 480
Db 1726 CTGACGATATGAGAAAGCAAAACCCCACTCATTGTTCTGAAAGAGAGAGAGTG 1785
QY 481 GAGCAACAAGGCTTTTGTGATTTGGGGGAACATGATGGCAGTCTTGACTTGGCATCAGA 540
Db 1786 GAGCAACAAGGCTTTTGTGATTTGGGGGAACATGATGGCAGTCTTGACTTGGCATCAGA 1845
QY 541 AGATCAGTTCAAGAAGGTAAATCCAAAGGCC 570
Db 1846 AGATCAGTTCAAGAAGGTAAATCCAAAGGCC 1875

RESULT 11
ABV22463
ID ABV22463 standard; cDNA; 1194 BP.
XX
AC ABV22463;
XX
DT 13-SEP-2002 (first entry)
XX
DE Human prostate expression marker cDNA 22454.
XX
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
XX pharmacogenomic marker; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200160860-A2.
XX
PD 23-AUG-2001.
XX
PF 20-FEB-2001; 2001WO-US05171.
XX
PR 17-FEB-2000; 2000US-183319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219077P.
PR 13-DEC-2000; 2000US-255281P.
XX
PA (MILT-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Schlegel R, Endege WO, Monahan JE;
XX
DR WPI; 2001-662795/76.
XX
```

```
PT Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer -
XX
PS Claim 1; Page 3912; 11750pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for:
CC (a) assessing whether a patient is afflicted with prostate cancer;
CC (b) monitoring the progression of prostate cancer in a patient;
CC (c) assessing the efficacy of a test compound to inhibit prostate
CC cancer in a patient;
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (I) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX
SQ Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;
XX
Query Match 96.2%; Score 548.4; DB 23; Length 1194;
Best Local Similarity 98.8%; Pred. No. 9e-160;
Matches 563; Conservative 0; Mismatches 6; Indels 1; Gaps 1;
QY 1 ATGATGAATTTCCAGCCCTCCGAGCAAAAGCCCTGGCGGCTCAGAGATGATGACTTCTTC 60
Db 531 ATGATGAATTTCCAGCCCTCCGAGCAAAAGCCCTGGCGGCTCAGAGATGATGACTTCTTC 590
QY 61 ATCTTGTGCTCTTTTCCATCTTTTCACCGGGGTCTTGTCACCCCTGGCCATCACATC 120
Db 591 ATCTTGTGCTCTTTTCCATCTTTTCACCGGGGTCTTGTCACCCCTGGCCATCACATC 650
QY 121 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCCTCTCTTCATTTCAC 180
Db 651 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCCTCTCTTCATTTCAC 710
QY 181 TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGCCTGGCTACCTGTGGTGTGG 240
Db 711 TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGCCTGGCTACCTGTGGTGTGG 770
QY 241 ATCTATCGAACCCTCATTTGGAAGTGTGCACCTTTTCATCTCTCACCCCTCATTTGTCTA 300
Db 771 ATCTATCGAACCCTCATTTGGAAGTGTGCACCTTTTCATCTCTCACCCCTCATTTGTCTA 830
QY 301 ATCATCACTATCTTTACTGCGACATCACAAGGGAAGGAAAGATTATGATTAAGGCTGCTC 360
Db 831 ATCATCACTATCTTTACTGCGACATCACAAGGGAAGGAAAGATTATGATTAAGGCTGCTC 890
QY 361 CATGACGAGATCATTTAATGAGGGCAAAAGATAAATGTTCTGTATGAAAAATTGATCAAG 420
Db 891 CATGACGAGATCATTTAATGAGGGCAAAAGATAAATGTTCTGTATGAAAAATTGATCAAG 950
QY 421 CTGACGATATGAGAAAGCAAAACCCCACTCATTGTTCTGAAAGAGAGAGAGTG 480
Db 951 CTGACGATATGAGAAAGCAAAACCCCACTCATTGTTCTGAAAGAGAGAGAGTG 1009
QY 481 GAGCAACAAGGCTTTTGTGATTTGGGGGAACATGATGGCAGTCTTGACTTGGCATCAGA 540
Db 1010 GAGCAACAAGGCTTTTGTGATTTGGGGGAACATGATGGCAGTCTTGACTTGGCATCAGA 1069
QY 541 AGATCAGTTCAAGAAGGTAAATCCAAAGGCC 570
Db 1070 CGATCAGTTCAAGAAGGTAAATCCAAAGGCC 1099

RESULT 12
ABV25683
ID ABV25683 standard; cDNA; 1194 BP.
XX
```

AC ABV25683;
XX
DT 16-SEP-2002 (first entry)
XX
DE Human prostate expression marker CDNA 25674.
XX
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
KW pharmacogenomic marker; gene; ss.
XX Homo sapiens.
XX WO200160860-A2.
XX
PD 23-AUG-2001.
XX
PF 20-FEB-2001; 2001WO-US05171.
XX
PR 17-FEB-2000; 2000US-183319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Schlegel R, Endege WO, Monahan JE;
XX WPI; 2001-662795/76.
DR
XX
PT Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer -
XX
PS Claim 1; Page 5146-5147; 11750pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for:
CC (a) assessing whether a patient is afflicted with prostate cancer;
CC (b) monitoring the progression of prostate cancer in a patient;
CC (c) assessing the efficacy of a test compound to inhibit prostate
CC cancer in a patient;
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (I) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX
SQ Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;

Query Match 96.2%; Score 548.4; DB 23; Length 1194;
Best Local Similarity 98.8%; Pred. No. 9e-160;
Matches 563; Conservative 0; Mismatches 6; Indels 1; Gaps 1;

QY 1 ATGATGAATTTCAGCCTCCGAGCAAAAGCCTGGCGGCTCAGATGATGACTTTCTTC 60
DB 531 ATGATGAATTTCAGCCTCCGAGCAAAAGCCTGGCGGCTCAGATGATGACTTTCTTC 590
QY 61 ATCTTCTGCTCTTTTCCCATCTTTACCGGGGCTTGTGCACCTGGCCATCACCATC 120
DB 591 ATCTTCTGCTCTTTTCCCATCTTTACCGGGGCTTGTGCACCTGGCCATCACCATC 650
QY 121 TGGAGATTGAAGCCTTACGCTGAGTGGCCCTTTTGAGGTCTGCTCTTCATTCAC 180
DB 651 TGGAGATTGAAGCCTTACGCTGAGTGGCCCTTTTGAGGTCTGCTCTTCATTCAC 710
QY 181 TCATCTACAGCTGATGACACCCCTAAGTACACGGCCGTGCTACCTGTGGTGTGG 240
DB 711 TCATCTACAGCTGATGACACCCCTAAGTACACGGCCGTGCTACCTGTGGTGTGG 770

QY 241 ATCTATCGGAACCTCATTTGAGTGTGCACTTTTTCATCCCTCACCCTCATTTGTGTA 300
DB 771 ATCTATCGGAACCTCATTTGAGTGTGCACTTTTTCATCCCTCACCCTCATTTGTGTA 830
QY 301 ATCATCACCTATCTTTACTGGCAGATCAGAGGGAAGAGATTATGATAAGGCTGCTC 360
DB 831 ATCATCACCTATCTTTACTGGCAGATCAGAGGGAAGAGATTATGATAAGGCTGCTC 890
QY 361 CATGAGCAGATCATTAATGAGGCAAGATAAATGTCTGTATAGAAAAATGATCAAG 420
DB 891 CATGAGCAGATCATTAATGAGGCAAGATAAATGTCTGTATAGAAAAATGATCAAG 950
QY 421 CTCAGGATATGAGAGAAAGCAAAACCCAGCTCATCTGTCTTGGAAAGAGAGAGCTG 480
DB 951 CTCAGGATATGAGAGAAAGCAAAACCCAGCTCATCTGTCTTGGAAAGAGAGAGCTG 1009
QY 481 GAGCAACAAGCCTTTTTCATTTGGGGGAGACATGATGGAGCTTGTACTTGGCATCTACA 540
DB 1010 GAGCAACAAGCCTTTTTCATTTGGGGGAGACATGATGGAGCTTGTACTTGGCATCTACA 1069
QY 541 AGATCAGTTCAGAGAGGTAATCCCAAGGCC 570
DB 1070 CGATCAGTTCAGAGAGGTAATCCCAAGGCC 1099

RESULT 13
ABV28278
ID ABV28278 standard; CDNA; 1194 BP.
XX
XX ABV28278;
AC
XX
DT 16-SEP-2002 (first entry)
XX
DE Human prostate expression marker CDNA 28269.
XX
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
KW pharmacogenomic marker; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200160860-A2.
XX
PD 23-AUG-2001.
XX
PF 20-FEB-2001; 2001WO-US05171.
XX
PR 17-FEB-2000; 2000US-183319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Schlegel R, Endege WO, Monahan JE;
XX WPI; 2001-662795/76.
DR
XX
PT Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer -
XX
PS Claim 1; Page 5881-5882; 11750pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for:
CC (a) assessing whether a patient is afflicted with prostate cancer;
CC (b) monitoring the progression of prostate cancer in a patient;
CC (c) assessing the efficacy of a test compound to inhibit prostate
CC cancer in a patient;

CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX
SQ Sequence 1194 BP, 288 A, 287 C, 278 G, 339 T, 2 other;

Query Match	96.28;	Score 548.4;	DB 23;	Length 1194;
Best Local Similarity	98.88;	Pred. No. 9e-160;		
Matches 563; Conservative	0;	Mismatches 6;	Indels 1;	Gaps 1;

OY	1	ATGATGAAATTTCCAGCCTCCGAGCAAAAGCCTGGCGGCGCTCACAGATGATGACTTTCTTC	60
Db	531	ATGATGAAATTTCCAGCCTCCGAGCAAAAGCCTGGCGGCGCTCACAGATGATGACTTTCTTC	590
OY	61	ATCTCTTGCCTCTTTTTCCTCCATCTTTCACCGGGGTCTGTGCAACCTGGCCATCACCATC	120
Db	591	ATCTCTTGCCTCTTTTTCCTCCATCTTTCACCGGGGTCTGTGCAACCTGGCCATCACCATC	650
OY	121	TGGAGATTGAAGCCTTTCAGCTGACTGTGGCCCTTTTCGAGGTGTGCCCTCTTCATTTCAC	180
Db	651	TGGAGATTGAAGCCTTTCAGCTGACTGTGGCCCTTTTCGAGGTGTGCCCTCTTCATTTCAC	710
OY	181	TCCATCTACAGCTGGATCGACACACCTTAAGTACACGGCCTGGCTACCTGTGGGTTGTTGG	240
Db	711	TCCATCTACAGCTGGATCGACACACCTTAAGTACACGGCCTGGCTACCTGTGGGTTGTTGG	770
OY	241	ATCTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTTCATCCTCACCCCTCATTTGCTA	300
Db	771	ATCTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTTCATCCTCACCCCTCATTTGCTA	830
OY	301	ATCATCACCTTAATCTTACTGGCAGATCACACAGAGGGAAGAAAGATTATGATAAGGCTGCTC	360
Db	831	ATCATCACCTTAATCTTACTGGCAGATCACACAGAGGGAAGAAAGATTATGATAAGGCTGCTC	890
OY	361	CATGACGAGATCATTAAATGAGGGCAAGATTAATGTCTCGATAGAAAATTGATCAAG	420
Db	891	CATGACGAGATCATTAAATGAGGGCAAGATTAATGTCTCGATAGAAAATTGATCAAG	950
OY	421	CTGCAGGATATGAGAAAGCAAAACCCAGCTCACTTGTTCGAAAAGAGAGAGGTG	480
Db	951	CTGCAGGATATGAGAAAGCAAAACCCAGCTCACTTGTTCGAAAAGAGAGAGGTG	1009
OY	481	GAGCAACAAGCCTTTTTCGATTTTGGGGGGAACATGATGCGCAGCTTGACTTTCGATCTAGA	540
Db	1010	GAGCAACAAGCCTTTTTCGATTTTGGGGGGAACATGATGCGCAGCTTGACTTTCGATCTAGA	1069
OY	541	AGATCAGTTCAAGAGGTTAATCCAAGGCC	570
Db	1070	CGATCAGTTCAAGAGGTTAATCCAAGGCC	1099

RESULT 14	
AAI09919	
ID	AAI09919 standard; cDNA; 501 BP.
XX	
AC	AAI09919;
XX	
DT	07-DEC-2001 (first entry)
XX	
DE	Human breast cancer expressed polynucleotide 2376.
XX	
KW	Human; breast cancer; cell marker; cytosstatic; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200151628-A2.
XX	
PD	19-JUL-2001.

XX 10-JAN-2001; 2001WO-US00798.
PF
XX 14-JAN-2000; 2000US-0176077.
PR 14-MAR-2000; 2000US-0189167.
PR 24-MAR-2000; 2000US-0192099.
PR 29-MAR-2000; 2000US-0193480.
PR 15-MAY-2000; 2000US-0205230.
PR 09-JUN-2000; 2000US-0211315.
PR 25-JUL-2000; 2000US-0220534.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Lillie J, Xu Y, Wang Y, Steinmann K;
XX
DR WPI; 2001-451856/48.
XX
XX New peptide useful as a marker for the diagnosis of breast cancer -
PT
XX
XX Claim 1; Page 455; 3695pp; English.
XX
XX The invention relates to human breast cancer expressed polynucleotides
CC (AAI07544-AAI26789) and methods of assessing whether a patient is
CC afflicted with breast cancer by examining the correlation between the
CC expression of certain markers and the cancerous state of breast cells.
CC The polynucleotides and encoded polypeptides are potential markers for
CC detecting, diagnosing, monitoring, characterising, treating and
CC potentially preventing breast cancer. The polynucleotides and encoded
CC polypeptides are also useful for isolating compounds with cytostatic
CC activity.

Sequence	501 BP;	147 A;	101 C;	128 G;	122 T;	3 other;
Query Match	63.7%;	Score 363;	DB 22;	Length 501;		
Best Local Similarity	98.4%;	Pred. No. 2.2e-102;				
Matches 366;	Conservative 0;	Mismatches 6;	Indels 0;	Gaps 0;		

QY	199	GACACCCTAAGTACACG	GCCCTGGCTACCTGTGGGTTGTTGGATCTATCGGAACCTCATT	258
Db	24	GCGGCGCGAGGTACACG	GCCCTGGCTACCTGTGGGTTGTTGGATCTATCGGAACCTCATT	83
QY	259	GGAAGTGTGCACCTCTTTT	TTTATCCTCACCCCTCATTTGTGCTATCATCACTATCTTTAC	318
Db	84	GGAAGTGTGCACCTCTTTT	TTTATCCTCACCCCTCATTTGTGCTATCATCACTATCTTTAC	143
QY	319	TGGCAGATTCACAGAGGG	GAAGGAAATATGATTAAGGCTGCTCCATGACAGATCATTTAAT	378
Db	144	TGGCAGATTCACAGAGGG	GAAGGAAATATGATTAAGGCTGCTCCATGACAGATCATTTAAT	203
QY	379	GAGGCGCAAGATAAATGT	TCTTGATAGAAAAATTGATCAAGCTGCAGATATGGAGAAG	438
Db	204	GAGGCGCAAGATAAATGT	TCTTGATAGAAAAATTGATCAAGCTGCAGATATGGAGAAG	263
QY	439	AAAGCAAAACCCACGCTC	ACTTCTTCTGGAAAAGAGAGAGGTGGAGCAACAAGGCTTTTGG	498
Db	264	AAAGCAAAACCCACGCTC	ACTTCTTCTGGAAAAGAGAGAGGTGGAGCAACAAGGCTTTTGG	323
QY	499	CATTTGGGGGAACATGAT	GCGAGTCTTTACTTGGCATCTAGAAAGTCAGTTCAGAAGGT	558
Db	324	CATTTGGGGGAACATGAT	GCGAGTCTTTACTTGGCATCTAGAAANATCAAGTTCAAGAAAGT	383
QY	559	AATCCAAGGGCC	570	
Db	384	AATCCAAGGGCC	395	

RESULT	15
AL18591	
ID	AL18591 standard; cDNA; 470 bp
XX	
AC	AL18591;
XX	
DT	07-DEC-2001 (first entry)

XX

DE Human breast cancer expressed polynucleotide 11048.

XX

KW Human; breast cancer; cell marker; cytostatic; ss.

XX

OS Homo sapiens.

XX

PN WO200151628-A2.

XX

PD 19-JUL-2001.

XX

PF 10-JAN-2001; 2001WO-US00798.

XX

PR 14-JAN-2000; 2000US-0176077.

PR 14-MAR-2000; 2000US-0189167.

PR 24-MAR-2000; 2000US-0192099.

PR 29-MAR-2000; 2000US-0193480.

PR 15-MAY-2000; 2000US-0205230.

PR 09-JUN-2000; 2000US-0211315.

PR 25-JUL-2000; 2000US-0220534.

XX

PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

XX

PI Little J, Xu Y, Wang Y, Steinmann K;

XX

DR WPI; 2001-451856/48.

XX

PT New peptide useful as a marker for the diagnosis of breast cancer -

XX

PS Claim 1; Page 1968; 3695pp; English.

XX

CC The invention relates to human breast cancer expressed polynucleotides (AA07544-AA076789) and methods of assessing whether a patient is afflicted with breast cancer by examining the correlation between the expression of certain markers and the cancerous state of breast cells. CC The polynucleotides and encoded polypeptides are potential markers for detecting, diagnosing, monitoring, characterising treating and CC potentially preventing breast cancer. The polynucleotides and encoded CC polypeptides are also useful for isolating compounds with cytostatic CC activity.

XX

SQ Sequence 470 BP; 144 A; 92 C; 116 G; 118 T; 0 other;

Query Match 63.6%; Score 362.4; DB 22; Length 470;

Best Local Similarity 99.7%; Pred. No. 3.3e-102;

Matches 363; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 207 AAGTACACGGCCCTGCTACCTGCTGGTGTGTTGATCTATCGGAACCTCATTTGGAAGTGT 266

Db 1 AAGTACACGGCCCTGCTACCTGCTGGTGTGTTGATCTATCGGAACCTCATTTGGAAGTGT 60

QY 267 GCACTTCTTTTTCATCTCACCCTCATTTGCTAATCATCACCTATCTTTACTGCGAGAT 326

Db 61 GCACTTCTTTTTCATCTCACCCTCATTTGCTAATCATCACCTATCTTTACTGCGAGAT 120

QY 327 CACAGAGGGAAGAGATTATGATAAGGCTGCTCCATGAGCAGATCATTAATGAGGGCAA 386

Db 121 CACAGAGGGAAGAGATTATGATAAGGCTGCTCCATGAGCAGATCATTAATGAGGGCAA 180

QY 387 AGATAAAATGTTCTGATAGAAAATGATCAAGCTGCAGATATGAGAGAAAGCAAA 446

Db 181 AGATAAAATGTTCTGATAGAAAATGATCAAGCTGCAGATATGAGAGAAAGCAAA 240

QY 447 CCCAGCTCAGTTGTTCTGAAAAGAGAGAGGTGAGCAACAAGGCTTTTTCATTGGG 506

Db 241 CCCAGCTCAGTTGTTCTGAAAAGAGAGAGGTGAGCAACAAGGCTTTTTCATTGGG 300

QY 507 GGAACATGATGGCAGTCTTGACTTGCATCTAGAGAATCAGTTCAAGAAGGTAATCCAAG 566

Db 301 GGAACATGATGGCAGTCTTGACTTGCATCTAGAGAATCAGTTCAAGAAGGTAATCCAAG 360

QY 567 GGCC 570

||||

Db 361 GGCC 364

Search completed: November 9, 2002, 01:52:20
Job time : 310 secs